ALTH: Summary for Allos Therapeutics, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, November 25, 2009, 2:28pm EST - Canadian Markets close in 1 hour and 32 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Allos Therapeutics, Inc. (ALTH)

At 14:13 EST: 6.55 USD

0.20 (3.15%)

MORE ON ALTH

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Allos Therapeutics, Inc. (NGM:ALTH) Delayed quote data

Last Trade:	6.55 USD
Trade Time:	2:13PM EST
Change:	0.20 (3.15%)
Prev Close:	6.35
Open:	6.32
Bid:	6.55 x 1300
Ask:	6.56 x 3100
1y Target Est:	12.22

Day's Range:	6.28 - 6.56
52wk Range:	4.68 - 9.30
Volume:	1,372,668
Avg Vol (3m):	2,984,940
Market Cap:	680.81M
P/E (ttm):	N/A
EPS (ttm):	-0.77
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ALTH to Portfolio

Download Data

HEADLINES

•	Dow slips 17 points; Whiting Petroleum leads Colorado gainers
	at bizjournals.com (Tue 5:05pm)

•	Healthcare Stocks: Safe and Speculative
	TheStreet.com TV (Tue 8:30am)

•	Coverage initiated on Allos Therapeutics by ThinkEquity
	Briefing.com (Tue 7:30am)

•	[video] Healthcare Stocks: Safe and Speculative
	at TheStreet.com (Mon, Nov 23)

•	A Big Upgrade for Allos Therapeutics
	at Motley Fool (Mon, Nov 23)

•	Dow escapes deeper loss Wednesday; Gasco Energy leads Colorado gainers
	at bizjournals.com (Wed, Nov 18)

•	Cramer's Stop Trading! Why Is Boeing Flying? (11/16/09)
	at Seeking Alpha (Tue, Nov 17)

•	Cramer's 'Stop Trading!': Bristol-Myers
	at TheStreet.com (Mon, Nov 16)

•	Cramer: Retail Investors Returning to Market?
	at CNBC (Mon, Nov 16)

•	Stock Smackdown: Cramer vs. CAPS
	at Motley Fool (Mon, Nov 16)

•	Allos Therapeutics Announces New Data on FOLOTYN to be Presented at the American Society of Hematology Meeting
	Business Wire (Wed, Nov 11)

More Headlines for ALTH...

ANALYST

EPS Est (next year) (Dec-09) :	-0.78
EPS Est (in 2 years) (Dec-10) :	-0.42
Avg Rec (current)*:	1.9
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumula...

Full Company Profile

Add to Portfolio

Email to a Friend

•